As part of the Medical & Scientific Organization I am responsible for setting the US & Global HEOR strategies and for the successful execution of HEOR projects and deliverables. This is through partnership with the functional US and Global areas including the Commercial & Market Access organizations, Scientific Communications, Clinical & Development organization and other internal and external partners/stakeholders.

Oversaw global execution of strategic plans for pipeline and marketed products in virology, neuroscience, and general medicine therapeutic areas (TAs) to obtain and maintain global market access, favorable pricing, and optimal formulary status. Worked closely with market access and medical affairs counterparts to influence and guide area and affiliate functions in developing consistent strategies for addressing reimbursement hurdles worldwide. Partnered with colleagues in key affiliate countries in development of tools serving as a core component of access strategy. Communicated key findings of HEOR research influencing strategic decision-making to internal leadership and external stakeholders and ensured findings integrated into drug development plans. - Maximized overall value of defined company products by generating evidence, as well as associated tools, to obtain and maintain market access, and gain optimal formulary status and pricing. - Launched several new products in HCV and Women’s Health. - Utilized and incorporated machine learning and AI in ensuring patient access; launch of MappingHepC - an interactive online resource committed to improving the awareness of chronic hepatitis C (Hep C) epidemiology in the United States https://mappinghepc.com/. - Drove RWE generation for all marketed products and the use of RWD, resulting in enhanced clinical trial enrollment (women’s health) and label expansion efforts (HCV). - Represented AbbVie on National Pharmaceutical Council Board (backup); University of Washington Corporate Advisory Board (CAB) and at PhRMA Foundation Health Advisory Panel & Value Assessment Committee http://www.phrmafoundation.org/leadership/advisory-committees/

Provided leadership in MA, HEOR, and MA & R strategies for all phases of products. Provided medical/scientific input and advice by working closely with R&D on early and late phase clinical trial(s) conducted in renal, autoimmune, CV, virology, and vaccines areas and led team of four regional medical affairs directors. Provided medical affairs expertise and input to global licensing and business development activities as well as all epidemiology work. Generated medical/scientific input for strategic business plans for MA & R into healthcare systems in all therapy areas, with specific focus in renal, autoimmune, CV, virology, and vaccines areas.

Bridged development and commercial organizations by providing HEOR, access and reimbursement, and pricing strategic leadership/direction for US products in the Cardiovascular, Oncology, Respiratory, ID, Vaccines, Neuroscience, and other GSK markets. Established and implemented strategic objectives for US pharma market to meet commercial needs of company regarding market access and reimbursement. Worked with matrix bodies within product development and commercialization groups to ensure provision of strategic and commercial health outcomes information for all TAs. Represented reimbursement market access, pricing, and policy needs for US pharma for compounds in development and through full lifecycle.

Cultivated US HO team and corresponding evidence to substantiate value of company’s portfolio of medicines in all phases of drug development. Built rigorous hormonal contraception model to launch Implanon (used in pricing and reimbursement decisions and allowed for rapid uptake by managed markets organizations). Constructed AMCP dossiers for Implanon, Tibolone, and other products. Developed models and other tools for Asenapine, new atypical antipsychotic. Acted as member of US and global commercialization teams and market access teams. Drafted HO strategy and tactics for Sugammedex, Nuvaring, and Follistim, as well as pipeline products in phases two and three.

Built world-class health outcomes team at Sanofi-Synthelabo (New York), encompassing economic, quality of life, statistical, and epidemiological expertise. Planned, generated, and disseminated economic and humanistic outcomes information for key products (including Plavix, Uroxatral, Ambien, Eloxatin, Elitek, Eligard, and Acomplia). Supported initiatives to include US Medical Affairs activities with statistics and analyses to develop critical epidemiological strategies and data. Hired nine PhD, MD, and PharmD level candidates to create world-class team supporting US medical and commercial organization in health outcomes, statistics, and epidemiology.

Created, developed, and conveyed to global customers the economic and humanistic value of Celebrex, Bextra, Xalatan, Detrol, Zyvox, Camptosar, Ambien, and Inspra. Managed budget of $12 million and led staff of 35 employees. Obtained positive formulary decisions in 80-plus managed care organizations in 2002. Submitted 100+ abstracts and publications and conducted 400+ pharmacoeconomic presentations to customers worldwide in 2002. Designed and developed responses to health authorities and regulatory agencies worldwide (NICE, CCHOTA, and PBAC) to obtain reimbursement for Celebrex and other key products.

Supported adoption and growth of Searle’s products by addressing the HO, pricing and reimbursement requirements, and access of these products into the US marketplace. Developed Health Outcomes evidence for Celebrex and other products from prospective and retrospective studies with managed care and other customers to obtain positive formulary status

Created commercial healthcare economics team to include strategic and tactical planning for marketed and pipeline products, disease management programs, strategic alliances, customer-initiated studies, and training programs in healthcare economics. Managed budget of $5 million and led staff of six full-time employees. Developed and implemented healthcare economic strategic plans for Lipitor, Rezulin, and Cerebyx to enable successful launches of core products into marketplace. Led health economic component in implementation of strategic disease management partnership with software company as well as introduction to customers to leverage PD products.

Provided strategic leadership for managed care marketing organization through development of customer alliances and marketing programs. Managed budget of $7 million and led staff of ten full-time employees. Created and managed Syntex clinical pharmacy liaison function (one of first in industry), composed of six field-based clinical and economic liaisons. Developed strategies for pipeline and in-line products for third-party reimbursement and pricing. Launched Aleve (in conjunction with Proctor & Gamble) into managed care marketplace and achieved record sales of $200 million in first year. Launched several generics and line-extensions, including Genora, into managed care.